Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $30074.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 4.42% to $30074.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $118325.0, a 62.89% decrease, with the full-year FY2025 number at $117052.0, up 2.8% from a year prior.
  • Depreciation & Amortization (CF) was $30074.0 for Q4 2025 at Outlook Therapeutics, up from $29737.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $30074.0 in Q4 2025 to a low of $28801.0 in Q4 2024.